The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform

Dong Fang - One of the best experts on this subject based on the ideXlab platform.

  • the efficacy of trimetazidine on Stable Angina Pectoris a meta analysis of randomized clinical trials
    International Journal of Cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P<0.001), fewer weekly nitroglycerin use (WMD=-0.98, 95%CI: -1.44 to -0.52, Z=4.19, P<0.001), longer time to 1mm ST-segment depression (WMD=0.30, 95%CI: 0.17 to 0.43, Z=4.46, P<0.001), higher total work (WMD=0.82, 95%CI: 0.44 to 1.20, Z=4.22, P<0.001) and longer exercise duration at peak exercise (WMD=49.81, 95%CI: 15.04 to 84.57, Z=6.38, P<0.001) than treatment of other anti-Anginal drugs for Stable Angina Pectoris. Sensitivity analysis was performed. Sub-group analysis showed that treatment duration was not a significant moderator and patients treated within 8 weeks and above 12 weeks had no difference in the outcomes addressed in this meta-analysis. No publish bias was detected. This meta-analysis confirms the efficacy of trimetazidine in the treatment of Stable Angina Pectoris, in comparison with conventional antiAnginal agents, regardless of treatment duration.

  • The efficacy of trimetazidine on Stable Angina Pectoris: A meta-analysis of randomized clinical trials
    International journal of cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P

Song Peng - One of the best experts on this subject based on the ideXlab platform.

  • the efficacy of trimetazidine on Stable Angina Pectoris a meta analysis of randomized clinical trials
    International Journal of Cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P<0.001), fewer weekly nitroglycerin use (WMD=-0.98, 95%CI: -1.44 to -0.52, Z=4.19, P<0.001), longer time to 1mm ST-segment depression (WMD=0.30, 95%CI: 0.17 to 0.43, Z=4.46, P<0.001), higher total work (WMD=0.82, 95%CI: 0.44 to 1.20, Z=4.22, P<0.001) and longer exercise duration at peak exercise (WMD=49.81, 95%CI: 15.04 to 84.57, Z=6.38, P<0.001) than treatment of other anti-Anginal drugs for Stable Angina Pectoris. Sensitivity analysis was performed. Sub-group analysis showed that treatment duration was not a significant moderator and patients treated within 8 weeks and above 12 weeks had no difference in the outcomes addressed in this meta-analysis. No publish bias was detected. This meta-analysis confirms the efficacy of trimetazidine in the treatment of Stable Angina Pectoris, in comparison with conventional antiAnginal agents, regardless of treatment duration.

  • The efficacy of trimetazidine on Stable Angina Pectoris: A meta-analysis of randomized clinical trials
    International journal of cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P

Zhijian Yang - One of the best experts on this subject based on the ideXlab platform.

  • Acupuncture therapy for the treatment of Stable Angina Pectoris: An updated meta-analysis of randomized controlled trials
    Complementary therapies in clinical practice, 2018
    Co-Authors: Yuan Liu, Haoyu Meng, Mohammad Reeaze Khurwolah, Jia-bao Liu, Heng Tang, Zhijian Yang
    Abstract:

    Abstract Background and purpose Stable Angina Pectoris is a common symptom imperiling patients’ life quality. The purpose of this meta-analysis is to assess the effectiveness of acupuncture alone or acupuncture plus medicine for the treatment of Stable Angina Pectoris. Methods Seven databases were searched ranging from 1959 to February 2018. Quantitative analysis of randomized controlled trials (RCTs) was performed by RevMan 5.3 software and STATA 12.0 program, and Cochrane criteria for risk-of-bias was used to assess the methodological quality of the trials. Results A total of 12 RCTs involving 974 patients were enrolled in this study. The pooled results showed that both acupuncture group (RR: 0.35, P  Conclusion Acupuncture therapy may improve Anginal symptoms and ECG results in patients with Stable Angina Pectoris, and can serve as an adjunctive treatment for this condition.

Qi Fang - One of the best experts on this subject based on the ideXlab platform.

  • the efficacy of trimetazidine on Stable Angina Pectoris a meta analysis of randomized clinical trials
    International Journal of Cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P<0.001), fewer weekly nitroglycerin use (WMD=-0.98, 95%CI: -1.44 to -0.52, Z=4.19, P<0.001), longer time to 1mm ST-segment depression (WMD=0.30, 95%CI: 0.17 to 0.43, Z=4.46, P<0.001), higher total work (WMD=0.82, 95%CI: 0.44 to 1.20, Z=4.22, P<0.001) and longer exercise duration at peak exercise (WMD=49.81, 95%CI: 15.04 to 84.57, Z=6.38, P<0.001) than treatment of other anti-Anginal drugs for Stable Angina Pectoris. Sensitivity analysis was performed. Sub-group analysis showed that treatment duration was not a significant moderator and patients treated within 8 weeks and above 12 weeks had no difference in the outcomes addressed in this meta-analysis. No publish bias was detected. This meta-analysis confirms the efficacy of trimetazidine in the treatment of Stable Angina Pectoris, in comparison with conventional antiAnginal agents, regardless of treatment duration.

  • The efficacy of trimetazidine on Stable Angina Pectoris: A meta-analysis of randomized clinical trials
    International journal of cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P

Jing Wan - One of the best experts on this subject based on the ideXlab platform.

  • the efficacy of trimetazidine on Stable Angina Pectoris a meta analysis of randomized clinical trials
    International Journal of Cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P<0.001), fewer weekly nitroglycerin use (WMD=-0.98, 95%CI: -1.44 to -0.52, Z=4.19, P<0.001), longer time to 1mm ST-segment depression (WMD=0.30, 95%CI: 0.17 to 0.43, Z=4.46, P<0.001), higher total work (WMD=0.82, 95%CI: 0.44 to 1.20, Z=4.22, P<0.001) and longer exercise duration at peak exercise (WMD=49.81, 95%CI: 15.04 to 84.57, Z=6.38, P<0.001) than treatment of other anti-Anginal drugs for Stable Angina Pectoris. Sensitivity analysis was performed. Sub-group analysis showed that treatment duration was not a significant moderator and patients treated within 8 weeks and above 12 weeks had no difference in the outcomes addressed in this meta-analysis. No publish bias was detected. This meta-analysis confirms the efficacy of trimetazidine in the treatment of Stable Angina Pectoris, in comparison with conventional antiAnginal agents, regardless of treatment duration.

  • The efficacy of trimetazidine on Stable Angina Pectoris: A meta-analysis of randomized clinical trials
    International journal of cardiology, 2014
    Co-Authors: Song Peng, Min Zhao, Jing Wan, Qi Fang, Dong Fang
    Abstract:

    This meta-analysis aimed to evaluate the efficacy of trimetazidine in combination with other anti-Anginal drugs versus other anti-Anginal drugs in the treatment of Stable Angina Pectoris (SAP). Randomized controlled trials (RCTs) published in English and Chinese were retrieved from computerized databases: Embase, PubMed, and CNKI. Primary outcomes consist of clinical parameters (numbers of weekly Angina attacks and nitroglycerin use) and ergometric parameters (time to 1mm ST-segment depression, and total work (in Mets) and exercise duration (in seconds) at peak exercise) in Stable Angina Pectoris treated by trimetazidine or not. The quality of studies was evaluated using Jadad score. Data analysis of 13 studies was performed using Stata 12.0 software. Results showed that treatment of trimetazidine and other anti-Anginal drugs was associated with a smaller weekly mean number of Angina attacks (WMD=-0.95, 95%CI: -1.30 to -0.61, Z=5.39, P